Drug Profile
Research programme: therapeutic agents - KineMed/Merck Serono
Latest Information Update: 30 Aug 2011
Price :
$50
*
At a glance
- Originator Merck Serono
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 30 Aug 2011 No development reported - Preclinical for Undefined indication in USA (unspecified route)
- 30 Aug 2007 Preclinical trials in Undefined indication in USA (unspecified route)